Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

News

Boris plants h in Tony Blair's is blue flag back yard.

Autor: IAN GALLAGHER ; JACINTA TAYLOR

Publikováno v: Mail on Sunday; 12/15/2019, p10, 2p

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AB0752 HOW DOES TIME TO DIAGNOSIS AND GENDER AFFECT TREATMENT OUTCOMES IN PATIENTS WITH ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY WITH SECUKINUMAB

Autor: K. Benesova, O. Hansen, U. Kiltz, J. Brandt-Juergens, P. Kästner, E. Riechers, D. Peterlik, C. Budden, A. Boas, S. Welle, H. P. Tony

Publikováno v: Annals of the Rheumatic Diseases. 81:1501-1502

BackgroundIn both, ankylosing spondylitis (AS) and psoriatic arthritis (PsA), women typically have a longer delay in diagnosis.1,2 There is scientific evidence that prognosis for AS and PsA improves when diagnosed early. The German non-interventional

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26b2d7f0304a934e0539176257669dde
https://doi.org/10.1136/annrheumdis-2022-eular.41

Zobrazit plný text záznamu

Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome

Autor: S Wiebecke, S Frantz, D Weismann, H P Tony, Marc Schmalzing, M J Steinhardt, H Klinker

Publikováno v: Scandinavian Journal of Rheumatology

While the majority of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections show a subacute development with mild to no symptoms, a severe course with acute respiratory distress s...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc94bf0d3a6a0898545135c44695e667
https://doi.org/10.1080/03009742.2020.1789734

Zobrazit plný text záznamu

Plný text ve formátu HTML

T cells, natural killer cells, and γδT cells in a large patient cohort with rheumatoid arthritis: influence of age and anti-rheumatic therapy

Autor: Renner R, Stefan Kleinert, Eva C. Schwaneck, Ottar Gadeholt, L. Junker, Michael Gernert, Marc Schmalzing, H-P Tony

Publikováno v: Scandinavian Journal of Rheumatology. 49:8-12

Objective: The aim of this cohort study was to evaluate the distribution of natural killer (NK) cells and T-cell subsets, including γδT cells, in the peripheral blood of patients with rheumatoid ar...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be1ccb2caf79d6e8d58844f1b357ca25
https://doi.org/10.1080/03009742.2019.1634755

Zobrazit plný text záznamu

Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw

Autor: Urs D.A. Müller-Richter, Eva C. Schwaneck, Ottar Gadeholt, Manuel Krone, H-P Tony, A. C. Kübler, S. Hartmann, A. Streit, Marc Schmalzing, R. Brands

Publikováno v: Zeitschrift für Rheumatologie. 79:203-209

The aim of the present study was to assess the prevalence of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients suffering from inflammatory rheumatic diseases, as well as to assess the prevalence of relevant dental, behavior

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d41e01393aaab88850328d2046ca176
https://doi.org/10.1007/s00393-019-0606-y

Zobrazit plný text záznamu

POS1013 HOW DOES BODY MASS INDEX AFFECT SECUKINUMAB TREATMENT OUTCOMES AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY

Autor: U. Kiltz, J. Brandt-Juergens, P. Kästner, E. Riechers, D. Peterlik, C. Budden, H. P. Tony

Publikováno v: Annals of the Rheumatic Diseases. 81:815.2-815

BackgroundThere is a higher prevalence of obesity in patients (pts) with psoriatic disease1. The German non-interventional study AQUILA provides real-world data on the influence of body mass index (BMI) of pts with psoriatic arthritis (PsA) on therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0398b5d4615e9e01bbe497adfa3d26f4
https://doi.org/10.1136/annrheumdis-2022-eular.40

Zobrazit plný text záznamu

OP0182 SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TitAIN TRIAL

Autor: N. Venhoff, W. A. Schmidt, R. Bergner, J. Rech, L. Unger, H. P. Tony, M. Mendelson, C. Sieder, M. Maricos, J. Thiel

Publikováno v: Annals of the Rheumatic Diseases. 81:121.2-122

BackgroundLittle is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs and symptoms of IL-17A driven medical conditions such as plaque

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5fa78b17c22f706c722553c2c80949a2
https://doi.org/10.1136/annrheumdis-2022-eular.806

Zobrazit plný text záznamu

OP0135 RISK OF CARDIOVASCULAR EVENTS UNDER JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONAL DATA FROM THE GERMAN RABBIT REGISTER

Autor: Y. Meissner, K. Albrecht, J. Kekow, S. Zinke, H. P. Tony, M. Schaefer, A. Strangfeld

Publikováno v: Annals of the Rheumatic Diseases. 81:86.2-87

BackgroundIn 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about the cardiovascular (CV) safety of the Janus kinase inhibitor (JAKi) tofacitinib and required changes in labelling. These actions were based on resul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::334eff4cf4cc7bd83702962911bc7da1
https://doi.org/10.1136/annrheumdis-2022-eular.779

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání